Janssen Announces U.S. FDA Approval of CABENUVA (rilpivirine and cabotegravir), the First Long-Acting Regimen for the Treatment of HIV
TITUSVILLE, N.J., January 21, 2021 – The Janssen Pharmaceutical Companies of Johnson &Johnson today announced the U.S. Food and Drug Administration (FDA) has approved CABENUVA (consisting of Janssen’s rilpivirine and ViiV Healthcare’s cabotegravir), the first and only once-monthly, long-acting regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults. The novel regimen was co-developed as part of a collaboration with ViiV Healthcare and builds on Janssen’s 25-year commitment to make HIV history. In the U.S., ViiV Healthcare is the marketing authorization holder for CABENUVA.CABENUVA is indicated as a complete regimen for the treatment of HIV-1 infection in adults to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen, with no history of treatment failure, and with no known or suspected resistance to either cabotegravir or rilpivirine. Prior to initiating treatment with CABENUVA, oral cabotegravir (VOCABRIA) and oral rilpivirine (EDURANT®) should be administered for approximately one month to assess the tolerability of each therapy.CABENUVA, a co-packaged kit with two injectable medicines, offers people living with HIV a new approach for maintaining viral suppression.1 Click to Tweet: #BREAKING: The #FDA has approved another treatment option for people living with #HIV. Read full announcement here: http://...
Publication date: 15 February 2021Source: Journal of Hazardous Materials, Volume 404, Part BAuthor(s): Jinsoo Lee, Seong-Jin Choi, Ji-Seong Jeong, Sang Yun Kim, Sang-Hyub Lee, Mi Jin Yang, Seung-Jin Lee, Young-Jun Shin, Kyuhong Lee, Eun Ju Jeong, Sang-Yoon Nam, Wook-Joon Yu
We describe the most highly recommended generic and disease-specific PRO tools in SCD and discuss the challenges of incorporating them in clinical practice. EXPERT OPINION: PRO measures are essential to incorporate into SCD clinical trials either as primary or secondary outcomes. The use of PRO measures in SCD facilitates a patient-centered approach, which is likely to lead to improved outcomes. Significant challenges remain in adapting PRO tools to routine clinical use and in developing countries. PMID: 33034214 [PubMed - as supplied by publisher]
Authors: Bergland OU, Søraas CL, Larstorp ACK, Halvorsen LV, Hjørnholm U, Hoffman P, Høieggen A, Fadl Elmula FEM Abstract PURPOSE: The blood pressure (BP) lowering effect of renal sympathetic denervation (RDN) in treatment-resistant hypertension shows variation amongst the existing randomised studies. The long-term efficacy and safety of RDN require further investigation. For the first time, we report BP changes and safety up to 7 years after RDN, compared to drug adjustment in the randomised Oslo RDN study. MATERIALS AND METHODS: Patients with treatment-resistant hypertension, defined...
Authors: Zhang W, Xu JZ, Lu XH, Li H, Wang D, Wang JG Abstract PURPOSE: We hypothesise that dietary sodium intake interacts with serum uric acid to influence blood pressure (BP) in children and adolescents. In the present study, we investigated ambulatory BP in relation to hyperuricaemia, dietary sodium intake and their interaction in children and adolescents with hypertension. MATERIALS AND METHODS: A total of 616 study participants were 10-24 years old and had primary hypertension diagnosed after admission in a specialised inpatient ward. Ambulatory BP monitoring was performed during hospitalisat...
Publication date: November 2020Source: Language &Communication, Volume 75Author(s): Ben Ó Ceallaigh
Publication date: January 2021Source: Safety Science, Volume 133Author(s): Helen Lingard, Tracy Cooke, Greg Zelic, James Harley
Currently in fellowship doing bread/butter procedures (MBB, epidurals, PNB, few SCS/PNS trials, etc.) and just interviewed at a private practice spot where they do a lot of procedures that I will have not done any training in prior to graduating (e.g. IT pump, SI fusion, Vertiflex, Kypho, MILD, Discectomy, lots of SCS/PNS trials etc) and significant amount of "OR pain procedures" at a very busy practice seeing 30-40 pts/day - how many of you are commonly performing these procedures and are... private practice concern
Conclusions: This review results revealed a low utilization of postnatal care service. Antenatal care service utilization has a positive effect on postnatal care service utilization. Policymakers and programmers better considered more antenatal care service use as one strategy of enhancing the utilization of postnatal care service. PMID: 33029402 [PubMed - in process]
More News: Allergy & Immunology | Australia Health | Autoimmune Disease | Biochemistry | Brain | Breastfed | Canada Health | Cancer & Oncology | Carbamazepine | Cardiology | Cardiovascular | Chemistry | Child Development | Children | Chronic Pain | Clinical Trials | Conferences | Conjunctivitis | Depression | Dexamethasone | Drugs & Pharmacology | Epidemics | Epidemiology | Esomeprazole | Food and Drug Administration (FDA) | Gastroenterology | Genetics | Guillain-Barr Syndrome | Headache | Health Management | Heart | Hepatitis | Hepatitis B | Hepatitis Vaccine | Hypertension | Infectious Diseases | Insomnia | Internal Medicine | Ireland Health | Laboratory Medicine | Lansoprazole | Learning | Legislation | Liver | Liver Disease | Marketing | Migraine | Miscarriage | Neurology | Neuroscience | Nexium | Omeprazole | Pain | Pantoprazole | Pharmaceuticals | Phenobarbital | Phenytoin | Polymyositis | Postnatal Depression | Pregnancy | Prevacid | Prilosec | Profits and Losses | Protonix | Pulmonary Hypertension | Science | Skin | Sleep Disorders | Sleep Medicine | St John's Wort | Study | Suicide | Switzerland Health | Universities & Medical Training | Urology & Nephrology | USA Health | Vaccines | Virology | Warnings | Women